PL2427441T3 - Aktywatory PKM2 do stosowania w leczeniu raka - Google Patents

Aktywatory PKM2 do stosowania w leczeniu raka

Info

Publication number
PL2427441T3
PL2427441T3 PL10717982T PL10717982T PL2427441T3 PL 2427441 T3 PL2427441 T3 PL 2427441T3 PL 10717982 T PL10717982 T PL 10717982T PL 10717982 T PL10717982 T PL 10717982T PL 2427441 T3 PL2427441 T3 PL 2427441T3
Authority
PL
Poland
Prior art keywords
cancer
treatment
pkm2 activators
pkm2
activators
Prior art date
Application number
PL10717982T
Other languages
English (en)
Inventor
Francesco G. Salituro
Jeffrey O. Saunders
Original Assignee
Agios Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agios Pharmaceuticals, Inc. filed Critical Agios Pharmaceuticals, Inc.
Publication of PL2427441T3 publication Critical patent/PL2427441T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D263/00Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/58Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62Benzothiazoles
    • C07D277/68Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D339/00Heterocyclic compounds containing rings having two sulfur atoms as the only ring hetero atoms
    • C07D339/02Five-membered rings
    • C07D339/06Five-membered rings having the hetero atoms in positions 1 and 3, e.g. cyclic dithiocarbonates
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
PL10717982T 2009-05-04 2010-05-04 Aktywatory PKM2 do stosowania w leczeniu raka PL2427441T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US17521709P 2009-05-04 2009-05-04

Publications (1)

Publication Number Publication Date
PL2427441T3 true PL2427441T3 (pl) 2017-06-30

Family

ID=42200042

Family Applications (1)

Application Number Title Priority Date Filing Date
PL10717982T PL2427441T3 (pl) 2009-05-04 2010-05-04 Aktywatory PKM2 do stosowania w leczeniu raka

Country Status (7)

Country Link
US (1) US8501953B2 (pl)
EP (1) EP2427441B1 (pl)
CA (1) CA2760929C (pl)
DK (1) DK2427441T3 (pl)
ES (1) ES2619557T3 (pl)
PL (1) PL2427441T3 (pl)
WO (1) WO2010129596A1 (pl)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010105243A1 (en) 2009-03-13 2010-09-16 Agios Pharmaceuticals, Inc. Methods and compositions for cell-proliferation-related disorders
CA2758071C (en) 2009-04-06 2018-01-09 Agios Pharmaceuticals, Inc. Pyruvate kinase m2 modulators, therapeutic compositions and related methods of use
NZ597379A (en) 2009-06-29 2014-04-30 Agios Pharmaceuticals Inc Therapeutic compounds and compositions
PL2448581T3 (pl) * 2009-06-29 2017-06-30 Agios Pharmaceuticals, Inc. Kompozycje terapeutyczne i odnośne sposoby ich stosowania
WO2011009059A2 (en) * 2009-07-17 2011-01-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Method of treating or preventing cancer
CA2793835C (en) 2009-10-21 2021-07-20 Agios Pharmaceuticals, Inc. Methods and compositions for cell-proliferation-related disorders
US8692001B2 (en) 2010-10-27 2014-04-08 Dynamix Pharmaceuticals Ltd. Sulfonamides for the modulation of PKM2
CA2821975A1 (en) 2010-12-17 2012-06-21 Shunqi Yan N-(4-(azetidine-1-carbonyl)phenyl)-(hetero-) arylsulfonamide derivatives as pyruvate kinase m2 pkm2 modulators
ES2569712T3 (es) * 2010-12-21 2016-05-12 Agios Pharmaceuticals, Inc. Activadores de PKM2 bicíclicos
TWI549947B (zh) 2010-12-29 2016-09-21 阿吉歐斯製藥公司 治療化合物及組成物
HUE039269T2 (hu) 2011-05-03 2018-12-28 Agios Pharmaceuticals Inc Piruvát-kináz aktivátorok terápiában történõ alkalmazásra
US9181231B2 (en) 2011-05-03 2015-11-10 Agios Pharmaceuticals, Inc Pyruvate kinase activators for use for increasing lifetime of the red blood cells and treating anemia
CN103608016A (zh) 2011-05-03 2014-02-26 安吉奥斯医药品有限公司 丙酮酸激酶激活剂在治疗中的用途
CN102827170A (zh) 2011-06-17 2012-12-19 安吉奥斯医药品有限公司 治疗活性组合物和它们的使用方法
CN102827073A (zh) 2011-06-17 2012-12-19 安吉奥斯医药品有限公司 治疗活性组合物和它们的使用方法
WO2013056153A1 (en) * 2011-10-13 2013-04-18 Kung Charles Activators of pyruvate kinase m2 and methods of treating disease
EP2770995B1 (en) * 2011-10-28 2019-01-02 Merck Sharp & Dohme Corp. Benzoxazolinone compounds with selective activity in voltage-gated sodium channels
US9474779B2 (en) 2012-01-19 2016-10-25 Agios Pharmaceuticals, Inc. Therapeutically active compositions and their methods of use
MX365747B (es) 2012-10-15 2019-06-12 Agios Pharmaceuticals Inc Compuestos derivados de diarilurea de sulfonamida de arilo y sus usos.
JP6243918B2 (ja) 2012-10-16 2017-12-06 トレロ ファーマシューティカルズ, インコーポレイテッド Pkm2調節因子およびそれらの使用方法
KR20150074122A (ko) * 2012-10-26 2015-07-01 머크 샤프 앤드 돔 코포레이션 전압-게이팅 나트륨 채널에서 선택적 활성을 갖는 벤족사졸리논 화합물
WO2014139144A1 (en) 2013-03-15 2014-09-18 Agios Pharmaceuticals, Inc. Therapeutic compounds and compositions
WO2015003360A2 (en) 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
WO2015003355A2 (en) 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
US9579324B2 (en) 2013-07-11 2017-02-28 Agios Pharmaceuticals, Inc Therapeutically active compounds and their methods of use
US10376510B2 (en) 2013-07-11 2019-08-13 Agios Pharmaceuticals, Inc. 2,4- or 4,6-diaminopyrimidine compounds as IDH2 mutants inhibitors for the treatment of cancer
US20150031627A1 (en) 2013-07-25 2015-01-29 Agios Pharmaceuticals, Inc Therapeutically active compounds and their methods of use
KR20220070066A (ko) 2014-03-14 2022-05-27 아지오스 파마슈티컬스 아이엔씨. 치료적으로 활성인 화합물의 약제학적 조성물
SI3307271T1 (sl) 2015-06-11 2023-11-30 Agios Pharmaceuticals, Inc. Postopki za uporabo aktivatorjev piruvat kinaze
UA123401C2 (uk) 2015-10-15 2021-03-31 Аджиос Фармасьютікалз, Інк. Комбінована терапія для лікування злоякісних пухлин
BR122024000250A2 (pt) 2015-10-15 2024-02-27 Les Laboratoires Servier Uso de um inibidor de desidrogenase isocitrato 1 (idh1) mutante e um agente desmetilante de dna
RS60209B1 (sr) 2017-03-20 2020-06-30 Forma Therapeutics Inc Kompozicije pirolopirola kao aktivatori piruvat kinaze (pkr)
TW201908310A (zh) * 2017-05-11 2019-03-01 英商葛蘭素史克智慧財產發展有限公司 化合物
WO2019075367A1 (en) 2017-10-13 2019-04-18 Tolero Pharmaceuticals, Inc. PKM2 ACTIVATORS IN COMBINATION WITH OXYGEN REACTIVE SPECIES FOR THE TREATMENT OF CANCER
US10980788B2 (en) 2018-06-08 2021-04-20 Agios Pharmaceuticals, Inc. Therapy for treating malignancies
US10675274B2 (en) 2018-09-19 2020-06-09 Forma Therapeutics, Inc. Activating pyruvate kinase R
US20230055923A1 (en) 2018-09-19 2023-02-23 Forma Therapeutics, Inc. Activating pyruvate kinase r
EP3941463A1 (en) 2019-03-22 2022-01-26 Sumitomo Dainippon Pharma Oncology, Inc. Compositions comprising pkm2 modulators and methods of treatment using the same
WO2021072487A1 (en) * 2019-10-15 2021-04-22 TroBio Therapeutics Pty Ltd Sulfonamide compounds and the use thereof in the treatment of cancer
WO2022170200A1 (en) 2021-02-08 2022-08-11 Global Blood Therapeutics, Inc. 1-(2-sulfonyl-2,6-dihydropyrrolo[3,4-c]pyrazol-5(4h)-yl]-ethanone derivatives as pyruvate kinase (pkr) and pkm2 activators for the treatment of sickle cell disease

Family Cites Families (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE510563A (pl) * 1949-07-23
GB935538A (en) 1959-04-06 1963-08-28 Stop Motion Devices Corp Stop-motion head for use on knitting machines
GB1274436A (en) 1970-06-09 1972-05-17 Wolfen Filmfab Veb Process for the sensitization of photographic silver chloride and silver chlorobromide emulsions that may contain colour couplers
US3998828A (en) 1975-01-31 1976-12-21 Pfizer Inc. 4-[2-(1,3-Dialkyl-1,2,3,4-tetra-hydropyrimidine-2,4-dione-5-carboxamido)ethyl]-1-piperidine sulfonamide
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
DE2948434A1 (de) 1979-12-01 1981-06-11 Hoechst Ag, 6000 Frankfurt 1-piperidinsulfonylharnstoffe und verfahren zu ihrer herstellung
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
GB8325370D0 (en) * 1983-09-22 1983-10-26 Fujisawa Pharmaceutical Co Benzoxazoline and benzothiazoline derivatives
US4593102A (en) 1984-04-10 1986-06-03 A. H. Robins Company, Inc. N-[(amino)alkyl]-1-pyrrolidine, 1-piperidine and 1-homopiperidinecarboxamides (and thiocarboxamides) with sulfur linked substitution in the 2, 3 or 4-position
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
EP0246749A3 (en) 1986-05-17 1988-08-31 AgrEvo UK Limited Triazole herbicides
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US4775762A (en) 1987-05-11 1988-10-04 The Dow Chemical Company Novel (1H-1,2,3-triazol-1-yl)pyridines
US5962490A (en) 1987-09-25 1999-10-05 Texas Biotechnology Corporation Thienyl-, furyl- and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
US5220028A (en) 1988-10-27 1993-06-15 Nissan Chemical Industries, Ltd. Halogeno-4-methylpyrazoles
MY106533A (en) 1990-02-20 1995-06-30 Sumitomo Chemical Co A 4-tert.-butyl imidazole derivative and its production and use.
CA2036147A1 (en) 1990-06-29 1991-12-30 Hiroki Tomioka A 1-pyridylimidazole derivative and its production and use
US5252590A (en) 1991-06-28 1993-10-12 Sumitomo Chemical Company, Limited 1-pyridylimidazole derivative
IT1252567B (it) 1991-12-20 1995-06-19 Italfarmaco Spa Derivati di 5-isochinolinsolfonammidi inibitori delle protein-chinasi
JP3409165B2 (ja) 1993-04-28 2003-05-26 株式会社林原生物化学研究所 養毛剤とその製造方法
ES2303337T3 (es) 1995-01-20 2008-08-01 G.D. Searle Llc Inhibidores de la proteasa retroviral de bis-hidroxietilamino sulfonamida.
GB9602166D0 (en) 1996-02-02 1996-04-03 Zeneca Ltd Aminoheterocyclic derivatives
US5843485A (en) 1996-06-28 1998-12-01 Incoe Corporation Valve-gate bushing for gas-assisted injection molding
DE19629335A1 (de) 1996-07-20 1998-01-22 Golden Records Ass Internation Karte aus Kunststoff
US6020357A (en) 1996-12-23 2000-02-01 Dupont Pharmaceuticals Company Nitrogen containing heteroaromatics as factor Xa inhibitors
DE19702988A1 (de) 1997-01-28 1998-07-30 Hoechst Ag Isoxazol- und Crotonsäureamidderivate und deren Verwendung als Arzneimittel und Diagnostika
EP0970072A1 (en) 1997-03-11 2000-01-12 E.I. Dupont De Nemours And Company Heteroaryl azole herbicides
US7863444B2 (en) 1997-03-19 2011-01-04 Abbott Laboratories 4-aminopyrrolopyrimidines as kinase inhibitors
US6106849A (en) 1998-01-21 2000-08-22 Dragoco Gerberding & Co. Ag Water soluble dry foam personal care product
AU754204B2 (en) 1998-09-01 2002-11-07 Bristol-Myers Squibb Company Potassium channel inhibitors and method
DE19841985A1 (de) 1998-09-03 2000-03-09 Schering Ag Dialkylsulfonsäure- und Dialkylcarbonsäure-Derivate
US6211182B1 (en) 1999-03-08 2001-04-03 Schering Corporation Imidazole compounds substituted with a six or seven membered heterocyclic ring containing two nitrogen atoms
US20010037689A1 (en) 2000-03-08 2001-11-08 Krouth Terrance F. Hydraulic actuator piston measurement apparatus and method
FR2817349B1 (fr) 2000-11-28 2003-06-20 Centre Nat Rech Scient Nouveau procede de criblage de modulateurs de la transcription bacterienne
DE10164711A1 (de) 2001-03-13 2002-10-17 Schebo Biotech Ag Verwendung von Zuckerphosphaten, Zuckerphosphatanalogen, Aminosäuren und/oder Aminosäureanalogen zur Modulation des Glycolyse-Enzym-Komplexes, des Malat Aspartat Shuttles und/oder der Transaminasen
AU2002256418A1 (en) 2001-04-27 2002-11-11 Vertex Pharmaceuticals Incorporated Inhibitors of bace
EP1387679A4 (en) 2001-05-07 2004-08-11 Smithkline Beecham Corp SULPHONAMIDES
US20040152648A1 (en) 2001-05-23 2004-08-05 Axel Ullrich Pyruvate-kinase as a novel target molecule
US6967212B2 (en) 2001-05-30 2005-11-22 Bristol-Myers Squibb Company Substituted azole acid derivatives useful as antidiabetic and antiobesity agents and method
JP4083397B2 (ja) 2001-06-18 2008-04-30 株式会社ルネサステクノロジ 半導体集積回路装置
CN1865258A (zh) 2001-08-15 2006-11-22 纳幕尔杜邦公司 用于控制无脊椎害虫的邻位取代的芳基酰胺化合物
US7148236B2 (en) * 2002-01-17 2006-12-12 Merck & Co., Inc. Modulators of acetylcholine receptors
WO2003073999A2 (en) 2002-03-01 2003-09-12 Pintex Pharmaceuticals, Inc. Pini-modulating compounds and methods of use thereof
GB0215775D0 (en) 2002-07-06 2002-08-14 Astex Technology Ltd Pharmaceutical compounds
EP1556040A1 (en) * 2002-10-24 2005-07-27 Sterix Limited Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 and type 2
US20070032418A1 (en) 2003-02-25 2007-02-08 Ambion, Inc Small-molecule inhibitors of angiogenin and rnases and in vivo and in vitro methods of using same
US20070099884A1 (en) 2003-06-06 2007-05-03 Erondu Ngozi E Combination therapy for the treatment of diabetes
US6818631B1 (en) 2003-08-15 2004-11-16 Nippon Soda Co. Ltd. Fungicidal pyrimidine derivatives
US20080051414A1 (en) 2003-10-14 2008-02-28 Arizona Board Of Regents On Behalf Of The University Of Arizona Protein Kinase Inhibitors
WO2005074946A1 (en) 2004-02-10 2005-08-18 Adenobio N.V. Stable and active complexes of adenosine and adenosine phosphates with aminoalcohols for the treatment of pulmonary artery hypertension, cardiac failure and other diseases
CA2556589A1 (en) 2004-02-24 2005-09-01 Bioaxone Therapeutique Inc. 4-substituted piperidine derivatives
US7588779B2 (en) 2004-05-28 2009-09-15 Andrx Labs, Llc Pharmaceutical formulation containing a biguanide and an angiotensin antagonist
EP1773310B9 (en) 2004-06-24 2012-04-25 Temple University - Of The Commonwealth System of Higher Education Alpha, beta-unsaturated sulfones, sulfoxides, sulfonimides, sulfinimides, acylsulfonamides and acylsulfinamides and therapeutic uses thereof
TW200606152A (en) 2004-07-02 2006-02-16 Tanabe Seiyaku Co Piperidine compound and process for preparing the same
FR2872704B1 (fr) 2004-07-12 2007-11-02 Laurent Schwartz Pluritherapie contre le cancer
EP1807417A2 (en) 2004-11-04 2007-07-18 Neurogen Corporation Pyrazolylmethyl heteroaryl derivatives
WO2006055880A2 (en) 2004-11-16 2006-05-26 Genzyme Corporation Diagnostic pkm2 methods and compositions
BRPI0607756A2 (pt) 2005-02-18 2010-05-18 Astrazeneca Ab composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, método para inibição de dna girase bacteriana e/ou topoisomerase iv em um animal de sangue quente, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, e, processo para preparar compostos ou sais farmaceuticamente aceitáveis dos mesmos
DE112006002052A5 (de) 2005-05-18 2008-05-08 Forschungsverbund Berlin E.V. Nicht-Peptidische Inhibitoren der AKAP-PKA-Wechselwirkung
CN101258135A (zh) 2005-07-05 2008-09-03 阿斯利康(瑞典)有限公司 新化合物、其制备方法、中间体、药物组合物和其在治疗5-ht6介导的疾病例如阿尔茨海默病、认知障碍、精神分裂症相关的认知缺损、肥胖和帕金森病中的用途
MX2008002723A (es) 2005-08-26 2008-03-26 Serono Lab Derivados de pirazina y uso como inhibidores de p13k.
FI20055644A0 (fi) 2005-12-02 2005-12-02 Nokia Corp Ryhmäviestintä
WO2007075524A2 (en) 2005-12-22 2007-07-05 Merck & Co., Inc. Substituted piperidines as calcium channel blockers
BRPI0706654A2 (pt) 2006-01-20 2011-04-05 Smithkline Beecham Corp composição farmacêutica, método para tratar condições ou distìrbios em um mamìfero, uso de um composto, e, composto
CN101448803A (zh) 2006-03-17 2009-06-03 阿斯利康(瑞典)有限公司 用作5-ht6调节剂的四氢萘
ES2614931T3 (es) 2006-08-04 2017-06-02 Beth Israel Deaconess Medical Center Inhibidores de la piruvato cinasa y métodos de tratamiento de enfermedad
CA2661741C (en) 2006-09-01 2014-04-29 Otsuka Chemical Co., Ltd. N-pyridylpiperidine compound, method for producing the same, and pest control agent
US7897776B2 (en) 2007-04-23 2011-03-01 Salutria Pharmaceuticals Llc Sulfonamide containing compounds for treatment of inflammatory disorders
US8552050B2 (en) 2007-08-16 2013-10-08 Beth Israel Deaconess Medical Center Activators of pyruvate kinase M2 and methods of treating disease
GT200800229A (es) 2007-10-26 2010-04-20 Novedosos derivados de imidazol
JP2011507910A (ja) 2007-12-21 2011-03-10 ユニバーシティー オブ ロチェスター 真核生物の寿命を変更するための方法
US8841305B2 (en) 2008-10-09 2014-09-23 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Activators of the human pyruvate kinase M2 receptor
WO2010105243A1 (en) 2009-03-13 2010-09-16 Agios Pharmaceuticals, Inc. Methods and compositions for cell-proliferation-related disorders
NZ597379A (en) 2009-06-29 2014-04-30 Agios Pharmaceuticals Inc Therapeutic compounds and compositions
WO2011153359A1 (en) 2010-06-04 2011-12-08 Albany Molecular Research, Inc. Glycine transporter-1 inhibitors, methods of making them, and uses thereof

Also Published As

Publication number Publication date
CA2760929A1 (en) 2010-11-11
EP2427441B1 (en) 2016-12-14
US20120122849A1 (en) 2012-05-17
US8501953B2 (en) 2013-08-06
ES2619557T3 (es) 2017-06-26
WO2010129596A1 (en) 2010-11-11
CA2760929C (en) 2018-01-02
DK2427441T3 (en) 2017-03-20
EP2427441A1 (en) 2012-03-14

Similar Documents

Publication Publication Date Title
PL2427441T3 (pl) Aktywatory PKM2 do stosowania w leczeniu raka
IL215108A0 (en) Amatoxin-armed target-binding moieties for the treatment of cancer
IL228597A0 (en) Isoindoline compounds for use in the treatment of cancer
ZA201207574B (en) Phytocannabinoids in the treatment of cancer
IL219992A0 (en) Combination therapy for treating cancer and dianostic assays for use therein
EP2482849A4 (en) COMBINED IMMUNOTHERAPY FOR THE TREATMENT OF CANCER
HK1175476A1 (en) Cancer treatment
GB201115711D0 (en) Phyto-cannabinoids for use in the treatment of cancer
GB0921596D0 (en) Particles for the treatment of cancer in combination with radiotherapy
EP2331520A4 (en) ROSAMINE DERIVATIVES AS AGENTS FOR CANCER TREATMENT
ZA201107879B (en) Composition for the treatment of prostate cancer
IL213761A0 (en) Novel ortho-aminoamides for the treatment of cancer
IL218971A0 (en) Sulfoxide derivatives for the treatment of tumours
IL217796A (en) Use of csf – g antagonists to delay metastasis
IL214349A0 (en) Compositions and methods for the treatment of cancer
HK1256479A1 (zh) 在治療癌症中grn163l用作端粒酶抑制劑
EP2437738A4 (en) METHOD AND COMPOSITIONS FOR CANCER TREATMENT
HK1151971A1 (en) Compounds for use in the treatment of cancer
IL210066A0 (en) Novel ortho-aminoanilides for the treatment of cancer
IL219298A0 (en) Triptans for the treatment of psoriasis
ZA201109508B (en) Methods of using corticotropin-releasing factor for the treatment of cancer
EP2411031A4 (en) Methods and compositions for the treatment of cancer
GB0901465D0 (en) Compounds for use in therapy
GB201718726D0 (en) Phytocannabinoids in the treatment of cancer
ZA201007729B (en) Use of corticotropin-releasing factor for the treatment of cancer